EcoDrugPlus

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSDARG00000004782
Gene Symbol: FGFR3
30 Enzyme and pathways 5 Cross references
194 Possible Orthologues:

Fms-Related Tyrosine Kinase 1 (Vascular Endothelial Growth Factor/vascular Permeability Factor Receptor)

Ensembl ID : ENSDARG00000019371
Gene Symbol: FLT1
6 Enzyme and pathways 5 Cross references
199 Possible Orthologues:

Fms-Related Tyrosine Kinase 4

Ensembl ID : ENSDARG00000104453
Gene Symbol: FLT4
5 Enzyme and pathways 5 Cross references
197 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSDARG00000102442
Gene Symbol: FOLR
17 Enzyme and pathways 5 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSDARG00000071494
Gene Symbol: FSHR
7 Enzyme and pathways 5 Cross references
201 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSDARG00000079661
Gene Symbol: LOC571502
7 Enzyme and pathways 5 Cross references
300 Possible Orthologues:

Fyn-Related Src Family Tyrosine Kinase

Ensembl ID : ENSDARG00000027807
Gene Symbol: FRK
8 Enzyme and pathways 5 Cross references
217 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSDARG00000036155
Gene Symbol: GLA
7 Enzyme and pathways 5 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 1

Ensembl ID : ENSDARG00000068989
Gene Symbol: GABRA1
4 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 3

Ensembl ID : ENSDARG00000090883
Gene Symbol: GABRA3
4 Enzyme and pathways 5 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 5

Ensembl ID : ENSDARG00000070730
Gene Symbol: GABRA5
4 Enzyme and pathways 5 Cross references
266 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) A Receptor, Alpha 6a

Ensembl ID : ENSDARG00000075058
Gene Symbol: GABRA6A
5 Cross references
195 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).